Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) CEO David P. Schenkein sold 27,000 shares of the company’s stock in a transaction on Wednesday, August 2nd. The shares were sold at an average price of $59.95, for a total value of $1,618,650.00. Following the completion of the transaction, the chief executive officer now directly owns 3,000 shares in the company, valued at approximately $179,850. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) opened at 61.46 on Friday. The company’s 50 day moving average price is $55.14 and its 200-day moving average price is $50.99. The stock’s market capitalization is $2.96 billion. Agios Pharmaceuticals, Inc. has a 52 week low of $35.84 and a 52 week high of $67.74.
Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($1.56) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.80) by $0.24. Agios Pharmaceuticals had a negative return on equity of 71.20% and a negative net margin of 491.54%. The firm had revenue of $10.51 million during the quarter, compared to analysts’ expectations of $9.65 million. During the same period in the previous year, the firm posted ($0.64) EPS. Agios Pharmaceuticals’s revenue for the quarter was down 66.4% on a year-over-year basis. Equities research analysts predict that Agios Pharmaceuticals, Inc. will post ($6.43) EPS for the current year.
TRADEMARK VIOLATION NOTICE: This story was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://stocknewstimes.com/2017/08/05/insider-selling-agios-pharmaceuticals-inc-nasdaqagio-ceo-sells-27000-shares-of-stock.html.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. C WorldWide Group Holding A S bought a new position in Agios Pharmaceuticals during the first quarter valued at approximately $105,000. Bank of Montreal Can boosted its position in Agios Pharmaceuticals by 11.7% in the first quarter. Bank of Montreal Can now owns 2,068 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 216 shares during the last quarter. Blue Sky Asset Management LLC bought a new position in Agios Pharmaceuticals during the first quarter valued at approximately $129,000. Russell Investments Group Ltd. boosted its position in Agios Pharmaceuticals by 163.9% in the first quarter. Russell Investments Group Ltd. now owns 2,549 shares of the biopharmaceutical company’s stock valued at $149,000 after buying an additional 1,583 shares during the last quarter. Finally, Advantage Investment Management LLC boosted its position in Agios Pharmaceuticals by 109.7% in the first quarter. Advantage Investment Management LLC now owns 3,250 shares of the biopharmaceutical company’s stock valued at $190,000 after buying an additional 1,700 shares during the last quarter. 84.24% of the stock is owned by hedge funds and other institutional investors.
Several equities analysts have commented on AGIO shares. Oppenheimer Holdings, Inc. set a $75.00 price objective on Agios Pharmaceuticals and gave the company a “buy” rating in a research report on Sunday, June 11th. ValuEngine raised Agios Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, June 2nd. Zacks Investment Research raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, April 28th. Canaccord Genuity set a $90.00 price objective on Agios Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, May 18th. Finally, Cann reaffirmed a “buy” rating and issued a $75.00 price objective on shares of Agios Pharmaceuticals in a research report on Wednesday, April 19th. Five analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $67.25.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
